Kyle Doherty

Total body irradiation followed by graft-versus-host disease prophylaxis is considered a feasible and effective regimen for both adult and pediatric patients, according to phase 2 study results.

Total body irradiation (TBI) regimen and myeloablative transplantation followed by a graft-versus-host disease (GVHD) prophylaxis regimen resulted in a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies

According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.

According to a phase 1/2 study, nivolumab plus PD-L1/IDO peptide vaccine may be effective for the treatment of patients with metastatic melanoma.

In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.

Two oncologists give their expert take on KRAS- and EGFR-mutant non–small cell lung cancer.

In light of the continued risks of COVID-19, especially for immunocompromised patients and those with cancer, physicians and guidelines have recommended vaccination including booster shots as soon as possible for all patients with cancer.

Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.

In patients with relapsed/peripheral T-cell lymphoma, the combination of duvelisib plus romidepsin was shown to be highly active.

Axicabtagene ciloleucel demonstrated a quality of life improvement in patients with large B-cell lymphoma as a second-line treatment compared with standard of care.

Based on findings from extended follow-up analysis of the phase 2 ELARA study, tisagenlecleucel is a beneficial treatment for patients with relapsed or refractory follicular lymphoma.

Liso-cel demonstrated meaningful EFS improvement as a second-line therapy in patients with LBCL.

Results from prespecified subgroup analyses of the phase KEYNOTE-522 study were presented during 2021 SABCS.

Phase 1 data indicate that ADP-A2AFP SPEAR T cells are effective and tolerable in patients with advanced hepatocellular carcinoma.

A study has confirmed that androgen receptor inhibition did not complicate robotic prostatectomy surgical outcomes in patients with prostate cancer.

In patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations, erdafitinib (Balversa) in combination with cetrelimab displayed clinically meaningful responses.

Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.

Prospective clinical trial results of lutetium-PSMA suggest the therapy is safe for patients with locally advanced high-risk prostate cancer.

A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.

A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

Data presented at the 2021 virtual ASCO Annual Meeting showed the benefits of adding nivolumab to chemotherapy treatment compared to chemotherapy alone, in patients with resectable non-small cell lung cancer.

The novel agent, zenocutuzumab demonstrated promise as treatment of patients with NRG1 fusion–positive cancers, in the phase 1/2 eNRGy study.

Progression-free survival and disease control in patients with advanced synovial sarcoma was improved by catequentinib.